Case report of clindamycin graded challenge in an AIDS patient allergic to clindamycin.

IF 1.6 Q3 ALLERGY

Asia Pacific Allergy Pub Date : 2022-10-17 eCollection Date: 2022-10-01 DOI:10.5415/apallergy.2022.12.e36

Thitinun Raknoo, Orawan Sae-Lim, Sutthiporn Pattharachayakul, Siripen Kanchanasuwan

引用次数: 2

Abstract

The aim of this study was to report the success of a clindamycin graded challenge. The patient was a 39-year-old human immunodeficiency virus-infected male with toxoplasmic encephalitis (TE) with a history of trimethoprim/sulfamethoxazole (TMP/SMX) and clindamycin allergy. He developed a reaction during TMP/SMX desensitization. Following the reaction, a graded challenge with clindamycin was performed in this study, and he became tolerant to clindamycin. No adverse drug reactions developed during the graded challenge. He successfully continued suppressive therapy with no further reactions or recurrences.

Abstract Image

查看原文本刊更多论文

克林霉素过敏的艾滋病患者克林霉素分级激射一例报告。

本研究的目的是报道克林霉素分级挑战的成功。患者为男性，39岁，感染人类免疫缺陷病毒，患有弓形浆性脑炎(TE)，有甲氧苄氨嘧啶/磺胺甲恶唑(TMP/SMX)和克林霉素过敏史。他在TMP/SMX脱敏过程中出现了反应。在此反应之后，本研究对克林霉素进行了分级挑战，他对克林霉素产生了耐受性。分级挑战期间未发生药物不良反应。他成功地继续抑制治疗，没有进一步的反应或复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia Pacific Allergy ALLERGY-

CiteScore

2.50

自引率

5.90%

发文量

期刊介绍： Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.